Crossmark

Cost-savings and potential cost-savings through the distribution of generic antiretroviral drugs within the statutory health insurance market of Germany between January 2017 and June 2019

Crossref DOI link: https://doi.org/10.1186/s12913-021-07390-4

Published Online: 2022-01-13

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lottes, Matthäus

Bremer, Viviane

Prugger, Christof

Kollan, Christian

Schmidt, Daniel
Funding

Funding for this research was provided by:

Robert Koch-Institut
License Information

Text and Data Mining valid from 2022-01-13

Version of Record valid from 2022-01-13
More Information

Article History

Received: 22 July 2021

Accepted: 7 December 2021

First Online: 13 January 2022

Declarations

:

: No administrative permissions were required to access the raw data. Insight Health™ provides the antiretroviral therapy prescription data on a regular basis to the Unit for HIV/AIDS, STI and Blood-borne Infections at the Robert Koch Institute for research purpose.

: ‘Not applicable’.

: ML, VB, CP and DS declare that they have no competing interests. CK is small shareholder in ABBV and JNJ (co) manufacturing the ATC codes J05AE03, J05AE10, J05AG04, J05AG05, J05AR10 and J05AR22.

Document is current

Any future updates will be listed below